In mice, removing an enzyme worsened MS-like disease

Credibility

Interest

Share:1 min read

Key Takeaway

In mice, removing an enzyme from certain immune cells worsened an MS-like disease.

What They Found

Brain scans of people with MS showed a link between inflammation in the brain's lining and certain chemicals. Researchers found a similar link in mice with an MS-like disease. Blocking an enzyme reduced one type of immune cell in the lining but increased another type. Removing the enzyme from the second cell type led to more of those cells and worse disease in mice. Those mice also had more disease-related immune proteins in their brains and fewer connections between nerve cells in one brain area.

Who Should Care and Why

The study involved people with MS and mice with an MS-like disease. The researchers did not report how many people took part. The human scans linked inflammation in the brain's lining with certain chemicals. The mouse experiments explored how an enzyme affects immune cells in that lining. The results may help explain a process involved in the mouse disease, but they do not show the same effects in people.

Important Considerations

The abstract does not give the number of people or mice studied. You cannot tell from the human scans whether the chemicals caused inflammation. You also cannot assume that blocking the enzyme would worsen MS in people.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research

Article Topics:

age associated B cellsautoimmunityimmunometabolismmultiple sclerosispolyamines

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Proceedings of the National Academy of Sciences of the United States of America often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News